Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2025)

Historic FCF Margin for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 78028.67%.

  • Crinetics Pharmaceuticals' FCF Margin changed N/A to 78028.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 23061.95%, marking a year-over-year decrease of 32748500.0%. This contributed to the annual value of 22118.77% for FY2024, which is 178577400.0% down from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' FCF Margin stood at 78028.67%.
  • Crinetics Pharmaceuticals' FCF Margin's 5-year high stood at 435.32% during Q1 2022, with a 5-year trough of 78028.67% in Q3 2025.
  • In the last 5 years, Crinetics Pharmaceuticals' FCF Margin had a median value of 8466.88% in 2024 and averaged 13378.34%.
  • Within the past 5 years, the most significant YoY rise in Crinetics Pharmaceuticals' FCF Margin was 35426600bps (2025), while the steepest drop was -163782800bps (2025).
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' FCF Margin stood at 2125.88% in 2021, then plummeted by -135bps to 5004.37% in 2022, then tumbled by -159bps to 12959.25% in 2023, then rose by 6bps to 12180.2% in 2024, then crashed by -541bps to 78028.67% in 2025.
  • Its last three reported values are 78028.67% in Q3 2025, 8637.54% for Q2 2025, and 24845.15% during Q1 2025.